Cardinal Health Inc

CAH remains in a long-term uptrend but has entered a Stage 3 distribution phase with medium-term lower highs & lower lows under declining short-term EMAs. Short-term price is rejecting at the 9/20 EMA zone, signaling bearish timing for selling. Execution should occur now, selling into the EMA resistance area on rejection.

• ↑Q3 revenue $61B (+11% YoY), driven by pharmaceutical and specialty demand.
• ↑Raised full-year EPS target to $10.70–$10.80, signaling ~30% growth.
• ↓Valuation stretched vs. peers on P/E multiple, risking correction.